Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions: DRUG: Ruxolitinib|DRUG: Exemestane
Sponsor: Abramson Cancer Center at Penn Medicine